Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Core Insights - The article emphasizes the importance of high-quality dividend investments for safeguarding and growing wealth in various market conditions [2]. Group 1: Investment Strategy - The investing group "The Dividend Kings" aims to assist investors in making informed decisions regarding dividend stocks [2]. - The group provides resources such as 13 model portfolios, buy ideas, and company research reports to enhance investment intelligence [2]. Group 2: Analyst Team - The team consists of several analysts, including Brad Thomas, Justin Law, Nicholas Ward, Chuck Carnevale, and Sebastian Wolf, who contribute to the investment insights [2]. - The community aspect is highlighted, with a thriving chat platform for members to learn and share knowledge about dividend investing [2].

Core Insights - HydroGraph Clean Power Inc. has appointed two new independent directors, Tom Wilkinson and Grant Duthie, to strengthen its board as the company transitions to commercial operations [1][2][3] Group 1: Board Appointments - The new directors bring extensive experience in operations, strategy, leadership, audit, governance, and public company management, aligning with the company's focus on innovation and growth [2][3] - The appointments fill vacancies left by the resignations of Paul Cox and David Williams, who left to pursue other business interests [5] Group 2: Company Transition - HydroGraph is moving from a development stage to commercial operations, with a growing pipeline of prospective customers for its graphene products across various end markets [3][4] - The company aims to secure its first commercial customers and build a scalable high-volume manufacturing facility to establish itself as a global leader in the graphene industry [4] Group 3: New Directors' Background - Tom Wilkinson has over thirty years of experience as a business leader and advisor, previously serving as CFO for Amelia Holdings and CEO for multiple technology companies [6][7] - Grant Duthie is a partner at Garfinkle & Biderman, focusing on securities, corporate finance, and M&A, with experience in advising various industry sectors [9][10]

Core Viewpoint - G-III Apparel Group reported solid first-quarter results for fiscal 2026, with earnings exceeding guidance, driven by strong performance in key owned brands despite the exit from Calvin Klein jeans and sportswear [2][3]. Financial Performance - Net sales for the first quarter decreased by 4% to $583.6 million compared to $609.7 million in the prior year [3][9]. - Net income for the first quarter was $7.8 million, or $0.17 per diluted share, up from $5.8 million, or $0.12 per diluted share, in the prior year [3][9]. - Non-GAAP net income per diluted share was $0.19, compared to $0.12 in the same period last year, excluding one-time severance expenses [4][9]. Balance Sheet Highlights - Inventories decreased by 5% to $456.5 million compared to $479.7 million last year [5]. - Total debt significantly decreased by 96% to $18.7 million from $426.4 million, following the redemption of $400 million in senior secured notes [6]. Capital Allocation - The company repurchased 807,437 shares for $19.7 million during the first quarter [7][9]. Outlook - G-III reaffirmed its net sales guidance for fiscal 2026, expecting approximately $3.14 billion in net sales, down from $3.18 billion in fiscal 2025 [10]. - The company anticipates net sales for the second quarter to be around $570 million, impacted by supply chain challenges [11]. - Net income for the second quarter is projected to be between $1.0 million and $6.0 million, a decrease from $24.2 million in the prior year [12].

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the “ ...

VANCOUVER, BC, June 06, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (“Eat & Beyond” or the “Company”), is pleased to announce that that globally recognized entrepreneur, investor, and citizen journalist Mario Nawfal has joined the Company as a Strategic Advisor. Mr. Nawfal is a force in modern media and Web3 innovation. As the founder of The Roundtable, X/Twitter’s most influential audio show, he has hosted global icons including Elon Musk, Marc Andreess ...

The primary goal of the Cash Flow Kingdom Income Portfolio is to produce an overall yield in the 7% - 10% range. We accomplish this by combining several different income streams to form an attractive, steady portfolio payout. The portfolio's price can fluctuate, but the income stream remains consistent. Start your free two-week trial today!He is a contributing author for the investing group Cash Flow Club where along with Darren McCammon, they focus on company cash flows and their access to capital. Core fe ...

ORLADEYO® (berotralstat) now reimbursed in the NetherlandsRESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major ...

SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- MoonFox Data, China’s leading provider of all-scenario data insights and analytics services, was recently invited to deliver a keynote address at the Neudata Hong Kong Data Summit 2025, held at the Hong Kong Cordis Hotel. Senior Analyst Max Ma presented "Navigating China's Market Pulse in 2025: Data-Driven Strategic Investment Insights," offering global investment institutions and enterprise clients an in-depth analysis of the latest trends in China's macro ...

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug ...